Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 3/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2938912 | 0.86 | CYP3A4 (0.42) | CCR5KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL1801039 | 0.85 | CXCR3 (0.44) | CCR5CXCR3KMT2AMEN1ABL1 | |
| SCHEMBL2943556 | 0.85 | LMNA (0.49) | CCR5KMT2AALDH1A1LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1799085 | 0.84 | CXCR3 (0.43) | CCR5CXCR3KMT2AMEN1ABL1 | |
| SCHEMBL4037038 | 0.83 | SMN1; SMN2 (0.41) | CCR5CXCR3KMT2ASMN1; SMN2GAA | |
| SCHEMBL1798796 | 0.83 | KMT2A (0.37) | KMT2AMEN1ABL1RIN1ALDH1A1 | |
| SCHEMBL2940845 | 0.82 | GRM5 (0.47) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2932813 | 0.82 | MEN1 (0.43) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1801308 | 0.82 | CCR5 (0.49) | CCR5ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2942516 | 0.81 | SMN1; SMN2 (0.48) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730147-B1 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | GRUENENTHAL GMBH (DE) | 2010-02-03 | — | — | EP | claimed |
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | SI, SSTR4, SLC10A2 | CCR5 4456/4885CXCR3 4786/4885KMT2A 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.